* Korro Bio Inc KRRO.OQ KRRO.O is expected to show no
change
in quarterly revenue when it reports results on May 10
(estimated) for the period ending January 1 0001
*
* LSEG's mean analyst estimate for Korro Bio Inc is for a
loss of
$2.51 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Korro Bio
Inc is
$117.50, above its last closing price of $54.01.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -2.57 -2.36 -25.65 Missed -985.3
Jan. 1 2023 -16.50 -17.72 -15.50 Beat 12.6
Jun. 30 2023 -17.34 -17.76 -15.00 Beat 15.6
Mar. 31 2023 -20.50 -21.02 -27.50 Missed -30.8
Jan. -28.50 -31.54 -24.50 Beat 22.3
1 0001
Jan. 1 0001 -27.97 -28.46 -27.50 Beat 3.4
Jun. 30 2022 -34.98 -33.65 -30.50 Beat 9.4
Mar. 31 2022 -31.06 -31.75 -33.50 Missed -5.5
This summary was machine generated May 8 at 11:33 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)